Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

ravulizumab 2 inebilizumab 2 rozanolixizumab 1 remibrutinib 1 iptacopan 1 fludarabine 1 efgartigimod alfa 1 Cyclophosphamide 1 Cladribine 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × efgartigimod alfa × 30 days × Clear all

NCT07217587 2026-06-05

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡